In the INTEREST trial (Efficacy and Safety of Interferon beta-1a in patients with ARDS), a multicenter, randomized, double-blind, parallel-group in 8 countries, 301 patients with moderate or severe ARDS were randomized to treatment with 10 μg of IFN-1a once daily for 6 days or to placebo (Ranieri et al., 2020). This evidence concerns the gene GDI1 and acute respiratory distress syndrome.